Table 2 –

Differences in Clinical Characteristics Between Cancer Survivors Who Received Paclitaxel and Did and Did Not Develop Peripheral Neuropathy

Characteristic	No PIPN 27.5% (n=58)	PIPN 72.5% (n=153)	Test, p-value
	Mean (SD)	Mean (SD)
Karnofsky Performance Status score	92.28 (8.02)	82.73 (10.42)	t= 7.01, <.001
Body mass index (kg/m2)	24.52 (4.55)	26.78 (5.92)	t= −2.62, .009
Number of comorbidities	1.35 (1.09)	1.93 (1.50)	t= −3.08, .002
SCO. score	2.63 (2.25)	3.99 (3.53)	t= −3.28, .001
AUDIT score	2.97 (1.96)	1.91 (1.95)	t= 3.50, .001
Years since cancer diagnosis	5.00 (4.77)	4.73 (4.63)	t= 0.38, .706
Number of prior cancer treatments	3.93 (0.73)	3.59 (0.83)	t= 2.85, .005
Number of current cancer treatments	0.74 (0.66)	0.67 (0.67)	t= 0.66, .508
Number of metastatic sites (out of 7)	0.77 (0.68)	0.72 (0.76)	MW, .388
Number of metastatic sites without lymph node involvement	0.09 (0.43)	0.12 (0.51)	MW, .727
	% (n)	% (n)
Smoker (ever)	31.6 (18)	34.0 (51)	FE, .869
Exercise on a regular basis (% yes)	89.3 (50)	84.9 (129)	FE, .503
Born prematurely (% yes)	1.7 (1)	7.8 (11)	FE, .186
Surgery on arms (% yes)	21.1 (12)	28.5 (43)	FE, .297
Surgery on hands (% yes)	1.7 (1)	9.3 (14)	FE, .073
Surgery on legs (% yes)	17.9 (10)	22.7 (34)	FE, .567
Surgery on feet (% yes)	16.1 (9)	20.7 (31)	FE, .555
Injury to arms (% yes)	29.3 (17)	29.1 (44)	FE, 1.000
Injury to hands (% yes)	14.3 (8)	38.5 (57)	FE,.001
Injury to legs (% yes)	17.9 (10)	19.3 (29)	FE, 1.000
Injury to feet (% yes)	29.1 (16)	26.7 (39)	FE,.726
Comorbid conditions (% yes)
Cancer	50.0 (29)	43.1 (66)	FE, .439
Osteoarthritis	13.8 (8)	31.4 (48)	FE, .009
Back pain	27.6 (16)	35.3 (54)	FE, .328
Depression	24.1 (14)	27.5 (42)	FE, .728
High blood pressure	12.1 (7)	26.8 (41)	FE, .027
Heart disease	0.0 (0)	5.9 (9)	FE, .066
Diabetes	1.7 (1)	5.2 (8)	FE, .450
Lung disease	1.7 (1)	3.9 (6)	FE, .676
Anemia or blood disease	1.7 (1)	5.9 (9)	FE, .291
Ulcer or stomach disease	0.0 (0)	4.6 (7)	FE, .194
Kidney disease	0.0 (0)	0.0 (0)	FE, 1.000
Liver disease	0.0 (0)	1.3 (2)	FE, 1.000
Rheumatoid arthritis	0.0 (0)	1.3 (2)	FE, 1.000
Pain not related to cancer	53.4 (31)	58.8 (90)	FE, .534
Type of cancer			X2=5.11, .078
Breast	93.1 (54)	98.0 (150)
Ovarian	0.0 (0)	0.7 (1)
Other	6.9 (4)	1.3 (2)
Any metastatic disease (% yes)	68.4 (39)	62.0 (93)	FE, .422
Dose of paclitaxel (mg/m2)	799.98 (208.50)	851.25 (718.90)	t= −0.51, .610
Patients who had a dose reduction or delay due to neuropathy (% (n))	0.0 (0)	13.6 (20)	FE, .001

Abbreviations: AUDIT = Alcohol Use Disorders Identification Test, FE = Fisher’s Exact test, kg = kilograms, m² = meters squared, mg = milligrams, PIPN = paclitaxel-induced peripheral neuropathy, SCQ = Self-Administered Comorbidity Questionnaire, SD = standard deviation, U = Mann Whitney U test